|
US8212004B2
(en)
|
1999-03-02 |
2012-07-03 |
Human Genome Sciences, Inc. |
Neutrokine-alpha fusion proteins
|
|
US6812327B1
(en)
|
1996-10-25 |
2004-11-02 |
Human Genome Sciences, Inc. |
Neutrokine-alpha polypeptides
|
|
WO2001060397A1
(en)
*
|
2000-02-16 |
2001-08-23 |
Genentech, Inc. |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
|
GB9828628D0
(en)
|
1998-12-23 |
1999-02-17 |
Glaxo Group Ltd |
Novel ligand
|
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
|
US20050100548A1
(en)
*
|
2001-07-24 |
2005-05-12 |
Biogen Idec Ma Inc. |
BAFF, inhibitors thereof and their use in the modulation of B-cell response
|
|
US20030095967A1
(en)
|
1999-01-25 |
2003-05-22 |
Mackay Fabienne |
BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
|
|
AU4986700A
(en)
|
1999-05-06 |
2000-11-21 |
National Jewish Medical And Research Center |
Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
|
|
CN100447244C
(zh)
|
1999-08-17 |
2008-12-31 |
比奥根艾迪克Ma公司 |
Baff受体(bcma),一种免疫调节剂
|
|
UA74798C2
(uk)
|
1999-10-06 |
2006-02-15 |
Байоджен Айдек Ма Інк. |
Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
US7371388B1
(en)
|
2000-05-04 |
2008-05-13 |
Human Genome Sciences, Inc. |
Treatment of Sjogren's syndrome by administration of TR18 polypeptides
|
|
WO2001087977A2
(en)
*
|
2000-05-12 |
2001-11-22 |
Amgen Inc. |
Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
|
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
PT2281843T
(pt)
|
2000-06-16 |
2017-01-02 |
Human Genome Sciences Inc |
Anticorpos que se ligam imunoespecificamente a blys
|
|
AU2001288301A1
(en)
|
2000-08-18 |
2002-03-04 |
Human Genome Sciences, Inc. |
Binding polypeptides and methods based thereon
|
|
UA83458C2
(uk)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
|
DE10049010A1
(de)
*
|
2000-10-04 |
2002-04-18 |
Boehringer Ingelheim Int |
Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen
|
|
BRPI0209933B8
(pt)
|
2001-05-24 |
2021-05-25 |
Zymogenetics Inc |
proteína de fusão, e, molécula de ácido nucleico
|
|
BR0211614A
(pt)
*
|
2001-08-03 |
2006-10-31 |
Genentech Inc |
polipeptìdeo tacis e br3 e empregos dos mesmos
|
|
US20080267965A1
(en)
*
|
2002-02-21 |
2008-10-30 |
Kalled Susan L |
Use of Bcma as an Immunoregulatory Agent
|
|
WO2004011611A2
(en)
*
|
2002-07-25 |
2004-02-05 |
Genentech, Inc. |
Taci antibodies and uses thereof
|
|
US7700317B2
(en)
|
2003-03-28 |
2010-04-20 |
Biogen Idec Ma Inc. |
Truncated baff receptors
|
|
JP2007526220A
(ja)
*
|
2003-06-05 |
2007-09-13 |
ジェネンテック・インコーポレーテッド |
Ｂ細胞疾患の併用療法
|
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
JP2007509064A
(ja)
|
2003-10-20 |
2007-04-12 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Ｂａｆｆアンタゴニストのための治療養生法
|
|
US20070249530A1
(en)
*
|
2004-01-29 |
2007-10-25 |
Genentech, Inc. |
Bcma Polypeptides and Uses Thereof
|
|
AU2005305182A1
(en)
*
|
2004-11-04 |
2006-05-18 |
Genentech, Inc. |
Polypeptides that bind BAFF and/or APRIL
|
|
US7947805B2
(en)
|
2004-12-23 |
2011-05-24 |
Merck Serono S.A. |
BCMA polypeptides and uses thereof
|
|
WO2006081516A2
(en)
*
|
2005-01-28 |
2006-08-03 |
Biogen Idec Ma Inc. |
USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS
|
|
EP1922080A2
(en)
|
2005-08-09 |
2008-05-21 |
ZymoGenetics, Inc. |
Methods for treating b-cell malignancies using taci-ig fusion molecule
|
|
WO2007019573A2
(en)
|
2005-08-09 |
2007-02-15 |
Zymogenetics, Inc. |
Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
|
|
WO2007142667A2
(en)
*
|
2005-10-13 |
2007-12-13 |
Human Genome Sciences, Inc. |
Treatment of patients with autoantibody positive disease
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
ES2618543T3
(es)
|
2005-11-23 |
2017-06-21 |
Genentech, Inc. |
Métodos y composiciones relacionados con ensayos de linfocitos B
|
|
WO2007123765A2
(en)
|
2006-03-31 |
2007-11-01 |
Human Genome Sciences Inc. |
Neutrokine-alpha and neutrokine-alpha splice variant
|
|
BRPI0711823A2
(pt)
|
2006-05-15 |
2012-01-17 |
Ares Trading Sa |
métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
|
|
SI2315780T1
(sl)
|
2008-07-17 |
2015-11-30 |
Novartis Ag |
Sestavki in postopki uporabe za terapevtska protitelesa
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
WO2010093993A2
(en)
*
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
|
MX341884B
(es)
*
|
2009-03-10 |
2016-09-07 |
Biogen Ma Inc |
Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
|
|
JP5996429B2
(ja)
|
2009-09-03 |
2016-09-21 |
ジェネンテック， インコーポレイテッド |
関節リウマチの治療、診断及びモニターするための方法
|
|
CN101781680B
(zh)
*
|
2009-10-19 |
2012-05-09 |
南通大学附属医院 |
测定对人baff-r基因启动子活性影响因素的方法
|
|
WO2011108008A2
(en)
*
|
2010-03-04 |
2011-09-09 |
Transgene Biotek Ltd. |
Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
|
|
MX353143B
(es)
|
2011-02-28 |
2017-12-20 |
Genentech Inc |
Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
|
|
KR101972446B1
(ko)
*
|
2011-05-27 |
2019-04-25 |
글락소 그룹 리미티드 |
Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
KR20140119777A
(ko)
|
2012-01-31 |
2014-10-10 |
제넨테크, 인크. |
항-ig-e m1'' 항체 및 그의 사용 방법
|
|
WO2015100246A1
(en)
|
2013-12-24 |
2015-07-02 |
Ossianix, Inc. |
Baff selective binding compounds and related methods
|
|
BR112016018100A2
(pt)
|
2014-02-07 |
2018-02-20 |
Univ Mcmaster |
acoplador antigênico de células t trifuncional, métodos e usos do mesmo
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
MY191537A
(en)
|
2014-12-05 |
2022-06-30 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
SI3226897T1
(sl)
|
2014-12-05 |
2021-08-31 |
Memorial Sloan Kettering Cancer Center |
Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US10294304B2
(en)
|
2015-04-13 |
2019-05-21 |
Pfizer Inc. |
Chimeric antigen receptors targeting B-cell maturation antigen
|
|
TWI703159B
(zh)
*
|
2015-04-13 |
2020-09-01 |
美商輝瑞股份有限公司 |
Bcma特異性治療性抗體及其用途
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
FI3380620T3
(fi)
|
2015-11-23 |
2024-08-01 |
Novartis Ag |
Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja
|
|
RU2018127657A
(ru)
|
2015-12-30 |
2020-01-31 |
Новартис Аг |
Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью
|
|
CN108778329B
(zh)
|
2016-02-17 |
2022-09-16 |
西雅图基因公司 |
Bcma抗体和其用以治疗癌症和免疫病症的用途
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
EP4628094A3
(en)
|
2016-06-06 |
2025-12-31 |
City of Hope |
BAFF-R ANTIBODIES AND THEIR USES
|
|
KR20250175345A
(ko)
|
2016-06-21 |
2025-12-16 |
테네오바이오, 인코포레이티드 |
Cd3 결합 항체
|
|
PE20241349A1
(es)
|
2016-09-14 |
2024-07-03 |
Teneobio Inc |
Anticuerpos de union a cd3
|
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
|
IL317134A
(en)
|
2016-12-21 |
2025-01-01 |
Teneobio Inc |
An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
|
|
ES2912408T3
(es)
|
2017-01-26 |
2022-05-25 |
Novartis Ag |
Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
|
|
CN110582509A
(zh)
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
MX2019013514A
(es)
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
KR20250007003A
(ko)
|
2017-06-20 |
2025-01-13 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
AU2018301393B2
(en)
|
2017-07-11 |
2025-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and uses thereof
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
CN111479925B
(zh)
|
2017-10-12 |
2024-03-08 |
麦克马斯特大学 |
具有y182t突变的t细胞-抗原偶联物及其方法和用途
|
|
AU2018351050B2
(en)
|
2017-10-18 |
2025-09-18 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
SG11202003501XA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
PT3703750T
(pt)
|
2017-11-01 |
2025-01-17 |
Memorial Sloan Kettering Cancer Center |
Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
|
|
MX2020004568A
(es)
|
2017-11-06 |
2020-10-05 |
Juno Therapeutics Inc |
Combinación de una terapia celular y un inhibidor de gamma secretasa.
|
|
CN111787938A
(zh)
|
2017-11-15 |
2020-10-16 |
诺华股份有限公司 |
靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
US20200371091A1
(en)
|
2017-11-30 |
2020-11-26 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
US12539308B2
(en)
|
2018-01-08 |
2026-02-03 |
The Trustees Of The University Of Pennsylvania |
Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
US20200399383A1
(en)
|
2018-02-13 |
2020-12-24 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
MX2020012028A
(es)
|
2018-05-11 |
2021-03-29 |
Crispr Therapeutics Ag |
Metodos y composiciones para tratar el cancer.
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
KR102870868B1
(ko)
|
2018-06-01 |
2025-10-15 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
TWI890660B
(zh)
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
MD3823665T2
(ro)
|
2018-07-19 |
2024-05-31 |
Regeneron Pharma |
Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
|
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP4635978A2
(en)
|
2018-08-31 |
2025-10-22 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
MA54078A
(fr)
|
2018-11-01 |
2021-09-15 |
Juno Therapeutics Inc |
Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
US20220152150A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
EP3942025A1
(en)
|
2019-03-21 |
2022-01-26 |
Novartis AG |
Car-t cell therapies with enhanced efficacy
|
|
WO2020206330A1
(en)
|
2019-04-05 |
2020-10-08 |
Teneobio, Inc. |
Heavy chain antibodies binding to psma
|
|
EP3953455A1
(en)
|
2019-04-12 |
2022-02-16 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
MX2021013359A
(es)
|
2019-04-30 |
2022-01-31 |
Crispr Therapeutics Ag |
Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
|
|
JP7489407B2
(ja)
|
2019-05-21 |
2024-05-23 |
ノバルティス アーゲー |
Ｃｄ１９結合分子及びその使用
|
|
CR20210622A
(es)
|
2019-06-14 |
2022-06-27 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
|
SG11202111943UA
(en)
|
2019-07-02 |
2021-11-29 |
Hutchinson Fred Cancer Res |
Recombinant ad35 vectors and related gene therapy improvements
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
BR112022011902A2
(pt)
|
2019-12-20 |
2022-09-06 |
Novartis Ag |
Terapias de combinação
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
EP4110376A2
(en)
|
2020-02-27 |
2023-01-04 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN115397460A
(zh)
|
2020-02-27 |
2022-11-25 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
IL297601A
(en)
|
2020-04-29 |
2022-12-01 |
Teneobio Inc |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
JP2023529211A
(ja)
|
2020-06-11 |
2023-07-07 |
ノバルティス アーゲー |
Ｚｂｔｂ３２阻害剤及びその使用
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
IL299826A
(en)
|
2020-07-15 |
2023-03-01 |
Cerebral Therapeutics Inc |
A medical device with a non-filtered CSF withdrawal path
|
|
JP7819176B2
(ja)
|
2020-08-03 |
2026-02-24 |
ノバルティス アーゲー |
ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
TW202220693A
(zh)
*
|
2020-08-12 |
2022-06-01 |
斯坦福大學托管董事會 |
sBCMA變異體及其FC融合蛋白
|
|
MX2023002107A
(es)
|
2020-08-21 |
2023-03-15 |
Novartis Ag |
Composiciones y metodos para la generacion in vivo de celulas que expresan car.
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
|
WO2022229853A1
(en)
|
2021-04-27 |
2022-11-03 |
Novartis Ag |
Viral vector production system
|
|
AU2022283819A1
(en)
|
2021-06-01 |
2024-01-04 |
Triumvira Immunologics Usa, Inc. |
Claudin 18.2 t cell-antigen couplers and uses thereof
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
KR20240053675A
(ko)
|
2021-08-11 |
2024-04-24 |
악소 바이오파마슈티컬 인코포레이티드 |
sBCMA 변이체 및 이의 FC 융합 단백질을 이용한 IgA, IgM 및/또는 IgG의 생산 감소 방법
|
|
EP4388000A1
(en)
|
2021-08-20 |
2024-06-26 |
Novartis AG |
Methods of making chimeric antigen receptor?expressing cells
|
|
US12605537B2
(en)
|
2022-02-15 |
2026-04-21 |
Biogen Ma Inc. |
Implantable medical device for use with or having recording electrode
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
AU2024239150A1
(en)
|
2023-03-21 |
2025-10-02 |
Biograph 55, Inc. |
Cd19/cd38 multispecific antibodies
|
|
PE20252789A1
(es)
|
2023-05-24 |
2025-12-22 |
Kumquat Biosciences Inc |
Compuestos heterociclicos y usos de estos
|
|
WO2025170844A1
(en)
*
|
2024-02-05 |
2025-08-14 |
Board Of Regents, The University Of Texas System |
Chimeric polypeptides and methods of use
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|